Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 4, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 4, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 40 Common Stock at $485.85 ($19,434) on September 4, 2026; holds 333,903 after (Indirect).
- Open-market sale: disposed of 223 Common Stock at $486.88 ($108,574) on September 4, 2026; holds 333,680 after (Indirect).
- Open-market sale: disposed of 2,818 Common Stock at $488.08 ($1,375,398) on September 4, 2026; holds 330,862 after (Indirect).
- Open-market sale: disposed of 3,425 Common Stock at $489.12 ($1,675,248) on September 4, 2026; holds 327,437 after (Indirect).
- Open-market sale: disposed of 1,514 Common Stock at $490.01 ($741,874) on September 4, 2026; holds 325,923 after (Indirect).
- Open-market sale: disposed of 1,160 Common Stock at $490.94 ($569,485) on September 4, 2026; holds 324,763 after (Indirect).
- Open-market sale: disposed of 320 Common Stock at $491.69 ($157,342) on September 4, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 4, 2026; holds 489,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,647,354 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-04 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-09-04 | Open-market sale | Common Stock | 40 | $486 | $19.4K | 333,903 |
| 2026-09-04 | Open-market sale | Common Stock | 223 | $487 | $108.6K | 333,680 |
| 2026-09-04 | Open-market sale | Common Stock | 2,818 | $488 | $1.4M | 330,862 |
| 2026-09-04 | Open-market sale | Common Stock | 3,425 | $489 | $1.7M | 327,437 |
| 2026-09-04 | Open-market sale | Common Stock | 1,514 | $490 | $741.9K | 325,923 |
| 2026-09-04 | Open-market sale | Common Stock | 1,160 | $491 | $569.5K | 324,763 |
| 2026-09-04 | Open-market sale | Common Stock | 320 | $492 | $157.3K | 324,443 |
| 2026-09-04 | Option exercise/conversion | Stock Option | 9,500 | — | — | 489,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-04 | Option exercise/conversion (9,500 shares) |
| 2026-09-04 | Open-market sale (40 shares) |
| 2026-09-04 | Open-market sale (223 shares) |
| 2026-09-04 | Open-market sale (2,818 shares) |
| 2026-09-04 | Open-market sale (3,425 shares) |
| 2026-09-04 | Open-market sale (1,514 shares) |
| 2026-09-04 | Open-market sale (1,160 shares) |
| 2026-09-04 | Open-market sale (320 shares) |
| 2026-09-04 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.